Global Womens Health Diagnostics Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

 Womens Health Diagnostics Market Size

• The global womens health diagnostics market size was valued at USD 34.51 billion in 2024 and is expected to reach USD 65.79 billion by 2032, at a CAGR of 8.4% during the forecast period
• This growth is driven by factors such as rising prevalence of female-specific diseases, growing awareness and screening initiatives, advancements in diagnostic technologies, increased healthcare access, and demand for personalized and preventive care

Womens Health Diagnostics Market Analysis

• Women’s health diagnostics encompass a range of tests and devices designed to detect diseases and monitor conditions unique to women, including reproductive health, cancers, and pregnancy-related issues. These diagnostics include imaging and monitoring systems, biopsy devices, reagents, and genetic testing kits, applied across hospitals, clinics, diagnostic centers, and home care settings
• The women’s health diagnostics market is witnessing robust growth fueled by increasing incidence of female-specific diseases, rising awareness and screening programs, technological advancements in diagnostic tools, growing focus on preventive healthcare and personalized medicine, and broader access to diagnostic services across both developed and emerging markets
• North America is expected to dominate the womens health diagnostics market with a share of with a share of 46.71%, due to the high adoption of technologically advanced diagnostic products, strong healthcare infrastructure, and an increasing focus on women-specific diseases
• Asia-Pacific is expected to be the fastest growing region in the womens health diagnostics market with a share of during the forecast period due to improving healthcare infrastructure, increasing government healthcare initiatives, and a growing awareness of women’s health disorders
• Breast cancer testing segment is expected to dominate the market due to high global prevalence of breast cancer, which is the most commonly diagnosed cancer among women. In addition, increasing awareness and government screening programs, along with technological advancements in imaging and molecular diagnostics (such as 3D mammography and genetic testing), are driving early detection and boosting demand. The strong pipeline of innovative diagnostic tools and growing adoption of personalized medicine also contribute to the segment’s leadership

Report Scope and Womens Health Diagnostics Market Segmentation

Womens Health Diagnostics Market Trends

“Increasing Adoption of Point-Of-Care Diagnostics”

• One prominent trend in the global womens health diagnostics market is the increasing adoption of point-of-care diagnostics
• This trend is driven by the rising need for rapid, accessible, and accurate diagnostic solutions, especially in remote or resource-limited settings, and the growing demand for immediate clinical decision-making in women’s health issues such as pregnancy, STDs, and infectious diseases 
  • For instance, Abbott offers the ID NOW platform, a rapid molecular point-of-care test used for detecting infectious diseases, while QuidelOrtho provides point-of-care solutions such as the Sofia platform for pregnancy and infectious disease testing 
• The convenience, speed, and reduced need for centralized lab infrastructure are making point-of-care diagnostics more appealing across both developed and emerging healthcare systems
• As healthcare models shift toward decentralized and patient-centered care, this trend is expected to significantly support market expansion and innovation in women’s health diagnostics

Womens Health Diagnostics Market Dynamics

Driver

“Rise in the Incidence of Infectious Diseases in Women”

• The rise in the incidence of infectious diseases in women is a key driver of growth in the women’s health diagnostics market, as there is an increasing need for accurate and rapid diagnostic solutions for conditions such as sexually transmitted diseases (STDs), urinary tract infections (UTIs), and reproductive health infections
• This demand is particularly strong among sexually active women, pregnant women, and those in high-risk environments
• As awareness of the impact of infectious diseases on women’s health grows, the market is witnessing a shift toward more accessible and non-invasive diagnostic methods for early detection
• Manufacturers are responding by launching innovative diagnostic tests, such as rapid molecular tests and home-testing kits, to provide quick results with minimal medical intervention
• The emphasis on improving women’s health through early intervention and prevention is driving the adoption of these diagnostic solutions

For instance,

• Companies such as Hologic have introduced advanced diagnostic tools such as the Panther Fusion system, which enables comprehensive testing for STDs and reproductive health infections
• Abbott and Cepheid also offer rapid diagnostic tests for women’s infectious diseases that can be used in point-of-care settings, improving accessibility and turnaround times 
• As the incidence of infectious diseases continues to rise, this driver is expected to significantly influence product innovation and expansion in the women’s health diagnostics market

Opportunity

“Enhanced Healthcare Infrastructure”

• Enhanced healthcare infrastructure presents a significant opportunity for the women’s health diagnostics market, as improved access to advanced diagnostic tools and services can help bridge the gap in healthcare disparities, particularly in underserved regions
• Healthcare providers and institutions are increasingly adopting cutting-edge diagnostic solutions to offer more comprehensive and timely services to women, including those related to reproductive health, cancer screening, and infectious disease testing
• This opportunity aligns with the growing demand for efficient and accessible healthcare, particularly in emerging markets where healthcare access is expanding rapidly

For instance,

• Companies such as GE Healthcare and Philips are integrating state-of-the-art imaging systems and diagnostic tools into hospitals and clinics, improving early detection of women-specific diseases
• Siemens Healthineers is also working on expanding access to diagnostic technology in developing countries, offering affordable and portable devices for women’s health screening 
• As healthcare infrastructure continues to improve globally, the women’s health diagnostics market is well-positioned to capitalize on this opportunity through greater market penetration and improved healthcare outcomes for women

Restraint/Challenge

“Increased Cost of Diagnostic Imaging Systems and Procedures”

• The increased cost of diagnostic imaging systems and procedures presents a significant challenge for the women’s health diagnostics market, as the high expense of advanced imaging technologies such as mammography, MRI, and ultrasound impacts both healthcare providers and patients
• The need to maintain high-quality diagnostic standards, while managing the growing costs of equipment and procedures, raises the overall expenses of women’s health diagnostics, making it difficult for healthcare systems, especially in low-resource settings, to provide affordable care without compromising service quality
• This challenge is particularly notable for smaller clinics, diagnostic centers, and healthcare providers targeting budget-conscious consumers, where high costs may limit the accessibility of essential screenings and diagnostic tests

For instance,

• Major healthcare companies such as GE Healthcare and Philips face rising costs in sourcing advanced imaging technology and maintaining these systems, which can influence their pricing strategies and accessibility for healthcare facilities, especially in developing regions 
• Without innovations in cost-effective diagnostic solutions or more efficient imaging technologies, the rising cost of diagnostic systems could slow market growth and limit accessibility, particularly in price-sensitive markets and underserved areas

Womens Health Diagnostics Market Scope

The market is segmented on the basis of diagnostic devices, application, and end user.

In 2025, the breast cancer testing is projected to dominate the market with a largest share in application segment

The breast cancer testing segment is expected to dominate the womens health diagnostics market due to high global prevalence of breast cancer, which is the most commonly diagnosed cancer among women. In addition, increasing awareness and government screening programs, along with technological advancements in imaging and molecular diagnostics (such as 3D mammography and genetic testing), are driving early detection and boosting demand. The strong pipeline of innovative diagnostic tools and growing adoption of personalized medicine also contribute to the segment’s leadership.

The imaging and monitoring systems is expected to account for the largest share during the forecast period in diagnostic devices market

In 2025, the imaging and monitoring systems segment is expected to dominate the market due to increasing demand for early and accurate diagnosis of chronic conditions such as breast and ovarian cancer. The widespread use of advanced imaging technologies such as digital mammography, ultrasound, and MRI, especially in cancer screening programs, enhances detection rates and clinical outcomes.

Womens Health Diagnostics Market Regional Analysis

“North America Holds the Largest Share in the Womens health diagnostics Market”

• North America dominates the womens health diagnostics market with a share of 46.71%, driven by the high adoption of technologically advanced diagnostic products, strong healthcare infrastructure, and an increasing focus on women-specific diseases
• U.S. holds a significant share due to presence of major healthcare providers, ongoing innovations in diagnostic technology, and strong government initiatives supporting women’s health, such as affordable screening programs and funding for breast and cervical cancer research
• The region’s dominance is further supported by expanding access to healthcare services, a well-established reimbursement system for diagnostic procedures, and continuous product launches in the women’s health diagnostics space, particularly in areas such as cancer screening and prenatal genetic testing
• As the focus on women’s health continues to grow, North America is expected to maintain its dominant position in the global women’s health diagnostics market through 2032, driven by technological advancements and increasing awareness of women’s health issues

“Asia-Pacific is Projected to Register the Highest CAGR in the Womens health diagnostics Market”

• Asia-Pacific is expected to witness the highest growth rate in the womens health diagnostics market, driven by improving healthcare infrastructure, increasing government healthcare initiatives, and a growing awareness of women’s health disorders
• India holds a significant share due to rising middle-class population, growing participation of women in the workforce, and the increasing availability of diagnostic services in urban and rural areas
• The region’s growth is further fueled by the rise in health awareness campaigns, the expansion of diagnostic services in tier-2 and tier-3 cities, and greater access to affordable diagnostic technologies, including point-of-care devices
• With evolving healthcare infrastructure, government-driven healthcare reforms, and increasing awareness regarding women’s health, Asia-Pacific is poised to emerge as the fastest-growing region in the global women’s health diagnostics market through 2032

Womens Health Diagnostics Market Share

The market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to market.

The Major Market Leaders Operating in the Market Are:

• Siemens (Germany)
• Hologic, Inc. (U.S.)
• Shenzhen Mindray Bio-Medical Electronics Co., Ltd. (China)
• Abbott (U.S.)
• BD (U.S.)
• F. Hoffmann-La Roche Ltd (Switzerland)
• Thermo Fisher Scientific (U.S.)
• Koninklijke Philips N.V. (Netherlands)
• NeuroLogica Corp. (U.S.)
• Shimadzu Corporation (Japan)
• bioMérieux SA (France)
• Carestream Health (U.S.)
• MEDGYN PRODUCTS, INC. (U.S.)
• URIT MEDICAL ELECTRONIC CO., LTD (China)
• COOK (U.S.)
• Cardinal Health (U.S.)
• PerkinElmer Inc. (U.S.)
• General Electric Company (U.S.)
• Quest Diagnostics Incorporated (U.S.)
• Danaher Corporation (U.S.)
• Sysmex Corporation (Japan)
• Hitachi, Ltd. (Japan)
• Canon Inc. (Japan)
• FUJIFILM Holdings Corporation (Japan)

Latest Developments in Global Womens Health Diagnostics Market

• In October 2024, First Response launched the Multi Check Pregnancy Test Kit with an EasyCup, which combines a sample collection cup with an integrated test strip to simplify the testing process. This innovation improves user experience by offering multiple testing options and meeting consumer preferences for ease and control. The launch is expected to boost demand for pregnancy test kits by enhancing convenience and accessibility, aligning with the growing trend for at-home diagnostic solutions in the women’s health diagnostics market
• In October 2024, Yourgene Health and Genetix introduced Colombia's first local non-invasive prenatal testing (NIPT) service, using Yourgene's IONA Nx NIPT Workflow. This service provides rapid and accurate results for expectant parents, reducing reliance on overseas testing and lowering associated costs. The launch is poised to drive growth in the prenatal testing segment by making NIPT more accessible and affordable in Colombia, fostering greater market penetration in Latin America
• In June 2023, Salignostics launched its innovative Salistick saliva pregnancy test in the UK, providing an alternative to traditional urine tests. The device detects hCG hormone through a saliva sample and delivers results in just 5 to 15 minutes. This innovation is expected to impact the market by offering a more comfortable, convenient, and non-invasive testing method, meeting the growing demand for alternative and user-friendly diagnostic solutions in women’s health
• In September 2021, Terumo Aortic had announced the start of PANTHER, the company's global surgical transplant research. This prospective and retrospective multi-center, multi-arm post-market study looks at the company's whole line of knitted and woven surgical grafts and cardiovascular patches
• In June 2021, Illumina and Next Generation Genomic Thailand launched the VeriSeq NIPT Solution v2 for non-invasive prenatal testing in Thailand. This CE-IVD solution offers comprehensive fetal genome insights, detecting chromosomal anomalies beyond standard tests, and enables testing as early as 10 weeks via a single blood draw. The introduction of this advanced solution is expected to strengthen the prenatal testing market in Southeast Asia, enhancing the quality of pregnancy management and expanding access to high-precision diagnostic tools in the region 

SKU-12868